fda bpc-157 warning letter peptide panel narrowly backs unapproved drugs – NBC4 Washington FDA Sends Warning Letters to

The regulatory picture around compounding continues to evolve, so its worth checking current status with a prescribing physician

Heres what researchers have learned recently about neurokinin B and hot flashes: Neurokinin B was identified in a genome-wide association study as the only gene that plays a significant role in hot flashes (vasomotor symptoms).[ref] Another strong indication that neurokinin B is integral to hot flashes is that when neurokinin B is given to young women by IV, it triggers hot flashes in 80% of the women.[ref] A placebo-controlled clinical trial of an NK3R (neurokinin B receptor) antagonist drug, which blocks the neurokinin B receptor, showed that it quickly reduced hot flash frequency by more than half compared to a placebo.[ref][ref] The emerging picture is that hot flashes involve body temperature mechanisms in the hypothalamus that are affected by estrogen and neurokinin B, which in turn affect FSH and LH levels

Not intended to diagnose, treat, cure, or prevent disease without medical oversight.

Its the perfect time to ask questions and get a feel for the process

Your prescriber will determine the right approach for your goals

Please see our separate page Who Can Train